SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparednessKizzmekia S. Corbett, Barney S. Graham, Hamilton Bennett et al.|Nature|2020Cited by 1.7k
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primatesBryan E. Jones, Nicole V. Johnson, Patricia Brown‐Augsburger et al.|Science Translational Medicine|2021Cited by 503
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infectionBryan E. Jones, Jason S. McLellan, Patricia Brown‐Augsburger et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 175
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PreparednessKizzmekia S. Corbett, Tracy J. Ruckwardt, Darin K. Edwards et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 143
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functionsAndrea R. Shiakolas, Ivelin S. Georgiev, Kevin J. Kramer et al.|Cell Reports Medicine|2021Cited by 80